Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14939011 | 0.79 | NOS3 (0.34) | — | |
| SCHEMBL312626 | 0.74 | — | — | |
| SCHEMBL21801438 | 0.68 | PDE10A (0.30) | — | |
| SCHEMBL789698 | 0.67 | — | — | |
| SCHEMBL2019306 | 0.65 | CCR1 (0.48) | ADORA2AADORA1 | |
| SCHEMBL17971625 | 0.65 | IDH1 (0.33) | ADORA2AADORA1 | |
| SCHEMBL20600843 | 0.64 | HSP90AA1 (0.41) | ADORA2AADORA1 | |
| SCHEMBL16483444 | 0.64 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL8029519 | 0.64 | — | — | |
| SCHEMBL4861859 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-14 | — | — | US | claimed |
| EP-4259629-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-10-18 | — | — | EP | claimed |
| CN-116888119-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-10-13 | — | — | CN | claimed |
| WO-2022123272-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2022-06-16 | — | — | WO | claimed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | claimed |
| CN-102282140-A | New compounds 578 | — | 2011-12-14 | — | — | CN | claimed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-14 | — | — | US | disclosed |
| EP-4259629-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116888119-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022123272-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2022-06-16 | — | — | WO | disclosed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| CN-102282140-A | New compounds 578 | — | 2011-12-14 | — | — | CN | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | ADORA2A 623/4885ADORA1 925/4885 |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | ADORA2A 683/4885ADORA1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.